Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Topiramate

Drug and asset intelligence for Topiramate with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
7
Catalysts
2
Stage
Development stage unavailable

Sponsor company

Invagen Pharmaceuticals →

Mechanism of action

Combination Therapy

Recent signals(7)

RegulatoryAugust 3, 2026

FDA Accepts Supplement Application for Phentermine Hydrochloride and Topiramate

The FDA has accepted a supplemental application for Phentermine Hydrochloride and Topiramate submitted by Actavis Labs.

StrategyJuly 30, 2026

FDA Grants Approval for Biocon's Topiramate ANDA220943

The FDA has granted approval for Biocon Pharma's Abbreviated New Drug Application (ANDA) for Topiramate.

Strategy
July 29, 2026

FDA Grants AP Status for Topiramate ANDA079162 by Invagen Pharmaceuticals

The FDA has granted Abbreviated Approval (AP) status for the ANDA079162 application for Topiramate submitted by Invagen Pharmaceuticals.

RegulatoryJuly 21, 2026

FDA grants AP status for Phentermine Hydrochloride and Topiramate by Dr. Reddy's Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a combination of Phentermine Hydrochloride and Topiramate submitted by Dr. Reddy's Labs.

RegulatoryJuly 12, 2026

FDA grants supplemental approval for Phentermine Hydrochloride and Topiramate

The FDA has granted supplemental approval for the combination of Phentermine Hydrochloride and Topiramate under application ANDA204982.

RegulatoryJuly 6, 2026

FDA Grants AP Status for Topiramate Supplement by Invagen Pharmaceuticals

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement of Topiramate submitted by Invagen Pharmaceuticals.

CompetitiveJune 18, 2026

FDA Submission Update for Topiramate by Aiping Pharm Inc.

Aiping Pharm Inc. has submitted an application (ANDA078499) for Topiramate with a standard review priority.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

Invagen Pharmaceuticals — Topiramate

July 6, 2026 · N/A

Topline Data

— Topiramate

June 18, 2026 · N/A

Indications

Obesity →

Therapeutic areas

Anticonvulsant →
Antiepileptic →
Combination Therapy →
Neurology →
Neurology · Anticonvulsant →
Neurology · Antiepileptic →
Obesity →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.